191 related articles for article (PubMed ID: 1379967)
1. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof M; de Boer A; Magnani HN; Stiekema JC
Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
[TBL] [Abstract][Full Text] [Related]
2. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.
Stiekema JC; Van Griensven JM; Van Dinther TG; Cohen AF
Br J Clin Pharmacol; 1993 Jul; 36(1):51-6. PubMed ID: 8396956
[TBL] [Abstract][Full Text] [Related]
3. Orgaran (Org 10172): its pharmacological profile in experimental models.
Meuleman DG
Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
Ofosu FA
Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
Stiekema JC; Wijnand HP; Van Dinther TG; Moelker HC; Dawes J; Vinchenzo A; Toeberich H
Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354
[TBL] [Abstract][Full Text] [Related]
6. Orgaran in the prevention of deep vein thrombosis in stroke patients.
Turpie AG
Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969
[TBL] [Abstract][Full Text] [Related]
7. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
[TBL] [Abstract][Full Text] [Related]
8. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.
de Boer A; Stiekema JC; Danhof M; Breimer DD
J Clin Pharmacol; 1991 Jul; 31(7):611-7. PubMed ID: 1716644
[TBL] [Abstract][Full Text] [Related]
9. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.
Gallus A; Cade J; Ockelford P; Hepburn S; Maas M; Magnani H; Bucknall T; Stevens J; Porteous F
Thromb Haemost; 1993 Oct; 70(4):562-7. PubMed ID: 7509509
[TBL] [Abstract][Full Text] [Related]
10. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
Magnani HN
Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol.
Stiekema JC; de Boer A; Danhof M; Kroon C; Broekmans AW; van Dinther TG; Voerman J; Breimer DD
Haemostasis; 1990; 20(3):136-46. PubMed ID: 1696921
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne KR; McMahon LP; Becker GJ
Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
[TBL] [Abstract][Full Text] [Related]
13. [Heparin-induced thrombopenia during hemodialysis in intensive care: use of a low molecular weight heparinoid, ORG 10172 (Orgaran)].
Mahul P; Raynaud J; Favre JP; Jospé R; Décousus H; Auboyer C
Ann Fr Anesth Reanim; 1995; 14(1):29-32. PubMed ID: 7677282
[TBL] [Abstract][Full Text] [Related]
14. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
Zammit A; Dawes J
Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
[TBL] [Abstract][Full Text] [Related]
15. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
De Boer A; Stiekema JC; Danhof M; Breimer DD
Br J Clin Pharmacol; 1991 Jul; 32(1):23-9. PubMed ID: 1716140
[TBL] [Abstract][Full Text] [Related]
16. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
Cantor WJ; Leblanc K; Garvey B; Watson KR; Rasymas A; Strauss BH
Catheter Cardiovasc Interv; 1999 Mar; 46(3):352-5. PubMed ID: 10348139
[TBL] [Abstract][Full Text] [Related]
17. Orgaran in heparin-induced thrombocytopenia.
Chong BH; Magnani HN
Haemostasis; 1992; 22(2):85-91. PubMed ID: 1379968
[TBL] [Abstract][Full Text] [Related]
18. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B
Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
[TBL] [Abstract][Full Text] [Related]
20. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers.
de Boer A; Danhof M; Cohen AF; Magnani HN; Breimer DD
Thromb Haemost; 1991 Aug; 66(2):202-7. PubMed ID: 1722918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
